Clinical Study on Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia
Key facts
- Phase
- Phase 2
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 3 and 65 years old?
Source: NCT06378060, who can take part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Hematology department of the 920th hospital
- Trial code
- NCT06378060
- Record updated
- 22 April 2024
- Original description
The aim of this study was to evaluate the safety and efficacy of a modified allogeneic hematopoietic stem cell transplantation regimen for aplastic anemia.Read full original descriptionShow less
A Prospective, Multi-center, Single-arm Clinical Study to Evaluate the Safety and Efficacy of a Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia
The aim of this study was to evaluate the safety and efficacy of a modified allogeneic hematopoietic stem cell transplantation regimen for aplastic anemia.
Inclusion: Patients with benign or malignant hematological diseases such as leukemia, lymphoma, thalassemia, aplastic anemia, etc. diagnosed by NCCN guidelines, and requiring allogeneic hematopoietic stem cell transplantation as determined by the researchers; Age 3-65 years old; Weight 10Kg-100Kg; Eastern Cooperative Oncology Group (ECOG) score ≤3; No major organ injury (ECG ejection fraction >45%; bilirubin < 2 times the upper limit of normal value; AST and ALT < 3 times the upper limit of normal value; serum creatinine < 2 times the upper limit of normal value); No severe infection; Subjects voluntarily participated in this clinical trial and signed the informed consent.
Exclusion: patients with previous autologous or allogeneic hematopoietic stem cell transplantation; patients with nonhematologic diseases who are not eligible for transplantation or who do not wish to receive transplantation; patients with severe mental or neurological disorders that would affect the ability to provide informed consent and/or to report or observe adverse events; other conditions that the investigator determines to be inappropriate for enrollment; patients with an expected survival of less than 1 month; pregnant patients.